



IgG, to eliminate the anti-allotypic or isotypic antibodies,

- an immunoadsorption on an affinity column prepared with the anti-VEGF IgG, to purify the anti-idiotypes.

 --32. Pharmaceutical compositions, comprising as the active substance, an anti-idiotypic antibody according to claim 25.

 --33. Pharmaceutical compositions, comprising as the active substance, an anti-idiotypic antibody according to claim 26.

--34. Pharmaceutical compositions, comprising as the active substance the Fab fragment according to claim 27.

--35. Pharmaceutical compositions, comprising as the active substance the complex according to claim 29. --

R E M A R K S

A new set of claims 18-35 is presented herewith, highlighting the unity of invention which consists in an anti-idiotypic antibody which is directed against VEGF and has amongst other properties the following properties:

- being circulating,
- targeting angiogenic endothelial cells, without affecting quiescent cells,

- and binding to angiogenic endothelial cells (due to the fact that it is a ligand of the human KDR receptor).

Support for the additional elements appears for instance on page 5, lines 20-29.

What is now stressed in claim 18, is the "vectorization" property of the anti-idiotypic antibody of the invention.

In other words, said anti-idiotypic antibody promotes angiogenesis, and when it is coupled to a toxin or a radioactive element, inhibits angiogenesis.

Responsive to the requirement for election of species, applicants provisionally elect Species (1), inhibition of angiogenesis, with traverse. As noted above, it is believed to be apparent that the new claims 18-35 comport with the unity of invention requirement of PCT Rule 13. The Examiner will also appreciate that the form of new claims 18-35 is modified relative to the previous claims 1-17, according to the customary U.S. format, thereby to place those claims in better condition for examination on the merits.

Among the new claims 18-35, it is believed that at least claims 18, 19, 21, 23, 24, 29 and 35 are readable on the elected species.


PLOUET et al. S.N. 09/091,561

Favorable action on the merits of all of the pending claims 18-35 is accordingly respectfully requested.

Respectfully submitted,

YOUNG & THOMPSON

By


Andrew J. Patch
Attorney for Applicants
Registration No. 32,925
745 South 23rd Street
Arlington, VA 22202
Telephone: 703/521-2297

October 28, 1999